Peptide Antibiotics Global Market Report 2024

Peptide antibiotics are a type of antibiotics composed of peptides, and their antibacterial activity is based on the physical rupture of cell membranes. These antibiotics are designed to permeate bacterial membranes, accumulate within bacteria, and subsequently interfere with bacterial functioning.

The main types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics can either destroy or modify the drug, change the drug target, decrease or raise drug uptake, or substitute a different metabolic step as the medication's target. These antibiotics are antimicrobial peptides generated by ribosomes and produced by a wide range of species, from bacteria to plants and animals. Some examples of drugs under the category of peptide antibiotics include daptomycin, dalbavancin, telavancin, and other drugs used to treat various diseases such as skin infections, hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), bloodstream infections, and other conditions. Peptide antibiotics are utilized and distributed through channels like hospitals, homecare, specialty clinics, and other distribution channels.

The peptide antibiotics market research report is one of a series of new reports that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide antibiotics market size has grown rapidly in recent years. It will grow from $4.79 billion in 2023 to $5.31 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed in the historic period can be attributed to factors such as the discovery and development of peptide antibiotics, an increase in antibiotic resistance, a rise in the incidence of infectious diseases, advancements in peptide synthesis technologies, and the overall growth of the pharmaceutical industry.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The anticipated growth in the forecast period can be attributed to an emphasis on the development of novel antibiotics, the increasing global incidence of antibiotic-resistant infections, the expansion of research and development in antimicrobial peptides, and regulatory support for new antibiotic approvals. Major trends expected in the forecast period include the exploration of natural sources for antimicrobial peptides, the application of peptide antibiotics in animal health, a focus on peptide engineering for enhanced efficacy, the development of combination peptide antibiotics, and the integration of artificial intelligence and machine learning in peptide antibiotic discovery.

The growth of the peptide antibiotics market is anticipated to be propelled by the increasing prevalence of various infectious diseases. These diseases, caused by microorganisms like bacteria, fungi, and parasites, have witnessed a surge due to factors such as rapid urbanization, climate change, and an elevated risk of disease emergence. The demand for peptide antibiotics has risen in response to these trends, as they exert antibacterial activity by physically rupturing cell membranes. Notably, data from the Australian Institute of Health and Welfare revealed a substantial increase in notifiable infectious disease cases in Australia, rising from 2.89 million in 2020 to 7.02 million in 2021. This surge underscores the driving force of the growing incidence of infectious diseases in advancing the peptide antibiotics market.

Another significant driver for the peptide antibiotics market is the escalating incidence of chronic diseases. Chronic conditions, enduring for a year or more and requiring ongoing medical attention, have seen an uptick due to factors such as increased tobacco use, poor nutrition, and sedentary lifestyles. Peptide antibiotics play a crucial role in treating chronic diseases by delivering targeted drug administration. A report by the National Council on Aging, Inc., highlighted that over 85% of the elderly population grapples with at least one chronic illness, contributing to the annual healthcare spending in the US reaching $3.8 trillion. Hence, the rising prevalence of chronic conditions is a key factor propelling the growth of the peptide antibiotics market.

A prominent trend in the peptide antibiotics market is the increasing adoption of strategic partnerships among major companies. This collaborative approach allows companies to expand their market reach and leverage each other's resources effectively. For instance, Berkeley Lights, a US-based digital cell biology company, forged a strategic partnership with Aanika Biosciences in January 2022. Through this collaboration, Aanika Biosciences aims to utilize Berkeley Lights' high-throughput, functional screening service to rapidly identify and refine functional antimicrobial peptides (AMPs) targeting harmful bacteria, particularly those responsible for foodborne disease outbreaks. The partnership also involves the utilization of the Beacon Optofluidic Platform to identify peptides harmful to bacteria, leading to the development of a novel antibacterial tag. This tag will be integrated into Aanika Biosciences' bacterial spore-based barcoding technology to enhance food supply chain security.

Major players in the peptide antibiotics market are also making strategic moves by introducing generic versions, providing a cost-effective alternative for patients. Generic versions, which are off-patent alternatives to brand-name peptide-based antibiotics, offer affordability without compromising efficacy. In July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its portfolio by launching a generic version of Daptomycin for Injection. This peptide antibiotic is a cyclic lipopeptide synthesized by nonribosomal machinery and is prescribed for treating complicated skin and skin structure infections (cSSSI) in both adult and pediatric patients aged 1 to 17 years.

Major companies operating in the in the peptide antibiotics market report are Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Theravance Biopharma Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, AuroMedics Pharma LLC, EnBiotix Inc., Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, AdvaCare Pharma, Allecra Therapeutics GmbH, AmpliPhi Biosciences Corporation, Antabio, Arsanis Inc., Basilea Pharmaceutica Ltd., BioVersys AG, Curis Inc.

North America was the largest region in the peptide antibiotics market in 2023. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.